Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Immutep","sponsor":"University Hospital Pilsen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep Announces the Start of an Investigator-Initiated\n Phase II Study in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Starts Phase II Study of ArtemiC to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"MGC Pharmaceuticals"},{"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Pharmaceuticals Expands ArtemiC\u2122 Phase II Clinical Trial on COVID-19 Patients in Israel and India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"MGC Pharmaceuticals"},{"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Pharmaceuticals Provides ArtemiCTM Phase II Clinical Trial Results Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"MGC Pharmaceuticals"},{"company":"MGC Pharmaceuticals","sponsor":"Malta Enerprises","pharmaFlowCategory":"D","amount":"$3.7 million","upfrontCash":"$3.7 million","newsHeadline":"MGC Pharmaceuticals Receives Cash Grant to Help Establish ArtemiCTM Productioninn Malta","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"MGC Pharmaceuticals"},{"company":"ENA Respiratory","sponsor":"COPD Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"ENA Respiratory"},{"company":"ENA Respiratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"ENA Respiratory"},{"company":"ENA Respiratory","sponsor":"Blue Knight","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENA Respiratory Selected for BLUE KNIGHT\u2122 to Accelerate Development of Pan-Antiviral Nasal Spray","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"ENA Respiratory"},{"company":"Island Pharmaceuticals","sponsor":"State University of New York","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Island Pharmaceuticals Granted Key Patent for ISLA-101 in the United States","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Island Pharmaceuticals"},{"company":"Ampion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Ampion"}]

ENA Respiratory

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray

Details:

Pre-clinical research demonstrates that INNA-051 has pan-antiviral potential with efficacy against a variety of respiratory viruses, including SARS-CoV-2, influenza, and the common cold rhinovirus.

Lead Product(s): INNA-051

Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Blue Knight

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 12, 2022

ASK
US

Upload
your Pipeline Activity

ENA Respiratory

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray

Details:

ENA Respiratory begins influenza challenge study for fast-acting nasal spray INNA-051, a potent innate immune TLR2/6 agonist, designed to boost innate immunity in patients at high risk of severe complications from respiratory infections.

Lead Product(s): INNA-051

Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 15, 2022

ASK
US

Upload
your Pipeline Activity

ENA Respiratory

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray

Details:

The partnership adds INNA-051 to the COPD Foundation’s COPD360Net® pipeline and will utilize its global network of accredited centres, scientific expertise, and patient investigators to optimize and accelerate the clinical development program.

Lead Product(s): INNA-051

Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: COPD Foundation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership February 23, 2022

ASK
US

Upload
your Pipeline Activity

Ampion

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Ampio Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

Details:

The study will utilize inhaled Ampion™ to treat those suffering from respiratory distress due to COVID-19. Top-line results also showed that Ampion reduced all-cause mortality in COVID-19 respiratory distress by 78% for COVID-19 respiratory distress.

Lead Product(s): Aspartyl-alanyl-diketopiperazine

Therapeutic Area: Infections and Infectious Diseases Product Name: Ampion

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2021

ASK
US

Upload
your Pipeline Activity

Island Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Island Pharmaceuticals Granted Key Patent for ISLA-101 in the United States

Details:

ISLA-101, has been granted by the United States Patent & Trademark Office. ISLA-101 is a drug with a very well-known safety profile, being repurposed for mosquito borne viruses.

Lead Product(s): ISLA-101

Therapeutic Area: Infections and Infectious Diseases Product Name: ISLA-101

Highest Development Status: Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: State University of New York

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 19, 2021

ASK
US

Upload
your Pipeline Activity

MGC Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

MGC Pharmaceuticals Receives Cash Grant to Help Establish ArtemiCTM Productioninn Malta

Details:

The Malta facility will create a European manufacturing hub for ArtemiCTM with the ability to scale production to meet expected growing demand following positive clinical trial results.

Lead Product(s): Artemisinin,Curcumin,Boswellia Serrata

Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Malta Enerprises

Deal Size: $3.7 million Upfront Cash: $3.7 million

Deal Type: Funding December 22, 2020

ASK
US

Upload
your Pipeline Activity

MGC Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

MGC Pharmaceuticals Provides ArtemiCTM Phase II Clinical Trial Results Update

Details:

Interim Results reported to date demonstrate ArtemiCTM has met all primary end points for safety and efficacy, and FDA primary endpoint of sustained clinical recovery of COVID-19 patients.

Lead Product(s): Artemisinin,Curcumin,Frankincense

Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 07, 2020

ASK
US

Upload
your Pipeline Activity

Immutep

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients

Details:

Immutep will provide Efti at no cost to the University Hospital Pilsen which will fund the study. Investigator-initiated, placebo controlled and randomised Phase II study will be conducted evaluating eftilagimod alpha in up to 110 COVID-19 patients.

Lead Product(s): Eftilagimod Alpha

Therapeutic Area: Infections and Infectious Diseases Product Name: IMP321

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: University Hospital Pilsen

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement October 23, 2020

ASK
US

Upload
your Pipeline Activity

MGC Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

MGC Pharmaceuticals Expands ArtemiC™ Phase II Clinical Trial on COVID-19 Patients in Israel and India

Details:

The trial is assessing the safety and efficacy of the natural anti-inflammatory formulation ArtemiCTM, a natural supplement formula based on Artemisinin and Curcumin (along with supporting ingredients Vitamin C and Boswellia serrata) on COVID-19 Patients.

Lead Product(s): Artemisinin,Curcumin,Frankincense

Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 28, 2020

ASK
US

Upload
your Pipeline Activity

MGC Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

MGC Starts Phase II Study of ArtemiC to Treat Covid-19

Details:

The double-blind, placebo-controlled Phase II trial will investigate the safety and efficacy of ArtemiC, a natural formulation intended for immune-modulation.

Lead Product(s): ArtemiC

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY